A growing understanding of how “reproductive” hormones sculpt the brain could transform the management of neurological conditions.

Timberline Knolls, a mental health center owned by Acadia Healthcare, skimped on staff. Then came a series of tragedies.

The justices heard arguments in a constitutional challenge to a task force that decides what treatments are covered at no cost.

The White House is soliciting policy proposals designed to give women incentives to have more children, a priority for many social conservatives.

People with dementia often forget even close family members as the disease advances. “It can throw people into an existential crisis,” one expert said.

An interim U.S. attorney is demanding information about the selection of research articles and the role of N.I.H. Experts worry this will have a chilling effect on publications.

Government websites that once provided basic information about the virus now redirect to a page citing a number of misleading or heavily contested claims.

People in the community called the remarks dehumanizing and warned they could perpetuate harmful stigma.

Eli Lilly reported promising results from a study of its experimental oral drug that could rival popular injections to treat obesity and diabetes.

An internal memo proposes carving out $40 billion from federal health agencies while eliminating dozens of programs. Congress has ultimate appropriation authority.

Surges in Mennonite communities near the U.S. border may complicate containment efforts, experts say.

Clinical results of a GLP-1 in pill form showed safety and efficacy data similar to blockbuster injectable drugs.

The World Health Organization finally reached a compromise on a pandemic treaty after three years of talks. The United States withdrew from negotiations after President Trump took office.

The health secretary said he would prioritize studies into environmental causes while harshly discounting other factors scientists say are likely contributing to rising rates of the condition.

U.S. regulators are trying to shut down the industry for compounded weight-loss drugs, which could result in higher costs or suspend treatment for patients.